Phase 1 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with schizophrenia (confirmed through a specific psychiatric interview called the MINI) and whose condition is currently stable
- People who are taking one atypical antipsychotic medication only, at a dose that has not recently changed
- People who are currently receiving outpatient mental health care for schizophrenia from a psychiatric provider at the time of screening
- People whose antipsychotic medication is confirmed to be present in their blood at the baseline visit, based on a blood test taken at screening
- People who, if taking an antidepressant or anti-anxiety medication, have not had any dose changes in the 8 weeks before screening and will not have dose changes during the main treatment period
Who may not be able to join:
- People who have ever been diagnosed (now or at any point in their lifetime) with certain other mental health conditions, including intellectual disability, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, unspecified psychotic disorder, substance-induced psychotic disorder, bipolar disorder, or recurring or current major depressive disorder
- People who have had a moderate to severe problem with substance use — including alcohol — in the 6 months before screening (this does not apply to nicotine or caffeine)
- People who have used cannabis (marijuana or similar) more than 3 to 5 times in the past 30 days
- People who have had a stomach ulcer in the past 6 months, a history of upper gastrointestinal bleeding at any point in their life, an untreated H. pylori infection, or a diagnosis of Zollinger-Ellison syndrome
- People who are currently experiencing thoughts or intentions of harming others, as assessed by the trial investigator
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Screen Pass Rate; Exploratory Assessment-Specific Completion Rate; Total Assessment Completion Rate; Study Completion Rate; Adverse Events (AEs) Including AEs of Special Interest (AESI); Number of Participants with Abnormalities in Vital Signs; Number of Participants with Abnormalities in 12-lead Electrocardiogram (ECG); Number of Participants with Abnormalities in Laboratory Parameters; Number of Participants Reporting Changes in Body Weight; Number of Participants Reporting Changes in Body Mass Index (BMI); Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) Over Time; Extr...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.